provided
a standing, or “platform,” framework that used
adaptive randomization for the efficient, focused
clinical development of paired therapies and biomarkers.
The overall objective of the trial was to
reduce the cost, time, and number of patients that
were needed to identify effective drugs for the
treatment of aggressive, locally advanced breast
cancer